Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors

Pharmacological Reviews

Volumn 57, Issue 2, 2005, Pages 217-252

  Mollace, Vincenzo ^a   Muscoli, Carolina ^a   Masini, Emanuela ^b   Cuzzocrea, Salvatore ^c   Salvemini, Daniela ^d,e  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; ARL 17477; BICUCULLINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; ETODOLAC; GW 273629; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; S 2474; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SULINDAC; TACROLIMUS; TILMACOXIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERYL SALICYLATE;

ADENOMATOUS POLYP; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANGIOGENESIS; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; CANCER; CELL PROTECTION; COLON CANCER; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DNA SYNTHESIS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; EDEMA; EXCITOTOXICITY; GASTROINTESTINAL HEMORRHAGE; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; STROKE; THROMBOEMBOLISM; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 22944434894     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.57.2.1     Document Type: Review

References (466)

1. Abramson SB, Attur M, Amin AR, and Clancy R (2001) NO and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 3:535-541.
2. Ahlner J, Andersson RGG, Torfgard K, and Axelsson KL (1991) Organic nitrate esters: clinical use and mechanism of actions. Pharmacol Rev 43:351-423.
3. Aisaka K, Gross SS, Griffith OW, and Levi R (1989) L-Arginine availability determines the duration of acetylcholine-induced systemic vasodilation in vivo. Biochem Biophys Res Commun 163:710-717.
4. Alderton W, Angell A, Clayton N, Craig C, Dawson J, Frend A, McGill J, Moncada S, and Rees D (2000) GW274150 is a potent, long acting, highly selective inhibitor of inducible NO synthase (NOS-2) with therapeutic potential in post-operative ileus, in Biology of Nitric Oxide, pp 25-34, vol 7, Portland Press, London.
5. Alderton WK, Cooper CE, and Knowles RG (2001) NO synthases: structure, function and inhibition. Biochem J 357:593-615.
6. Almer G, Guegan C, Teismann P, Naini A, Rosoklija G, Hays AP, Chen C, and Przedborski S (2001) Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 49:176-185.
7. Alvarez B, Ferrer-Sueta G, Freeman BA, and Radi R (1999) Kinetics of peroxynitrite reaction with amino acids and human serum albumin. J Biol Chem 274:842-848.
8. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, Stuchin SA, Patel IR, and Abramson SB (1997) Superinduction of COX-2 activity in human osteoarthritis-affected cartilage. Influence of NO. J Clin Investig 99:1231-1237.
9. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, and Gregory SA (1996) Selective inhibition of COX (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Investig 97:2672-2679.
10. Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, and Zhang Y (2001) Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 21:8198-8209.
11. Anggard EE (1991) Endogenous nitrates-implications for treatment and prevention. Eur Heart J 12 (Suppl A):5-8.
12. Araki E, Forster C, Dubinsky JM, Ross ME, and Iadecola C (2001) Cyclooxygenase-2 inhibitor NS-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke 32:2370-2375.
13. Armstrong CP and Blower AL (1987) Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 28:527-532.
14. Babbedge RC, Hart SL, and Moore PK (1993) Anti-nociceptive activity of nitric oxide synthase inhibitors in the mouse: dissociation between the effect of L-NAME and L-NMMA. J Pharm Pharmacol 45:77-79.
15. Babu BR and Griffith OW (1998a) N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of NO synthase. J Biol Chem 273:8882-8889.
16. Babu BR and Griffith OW (1998b) Design of isoform-selective inhibitors of NO synthase. Curr Opin Chem Biol 2:491-500.
17. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, and Ryu WS (2001) Expression of COX-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7:1410-1418.
18. Bagetta G, Corasaniti MT, Paoletti AM, Berliocchi L, Nistico R, Giammarioli AM, Malorni W, and Finazzi-Agro A (1998) HIV-1 gp120-induced apoptosis in the rat neocortex involves enhanced expression of cyclo-oxygenase type 2 (COX-2). Biochem Biophys Res Commun 244:819-824.
19. Bailey JM, Muza B, Hla T, and Salata K (1985) Restoration of prostacyclin synthase in vascular smooth muscle cells after aspirin treatment: regulation by epidermal growth factor. J Lipid Res 26:54-61.
20. Balligand JL, Kelly RA, Marsden PA, Smith TW, and Michel T (1993) Control of cardiac muscle cell function by an endogenous NO signaling system. Proc Natl Acad Sci USA 90:347-351.
21. Bandarage UK, Chen L, Fang X, Garvey DS, Glavin A, Janero DR, Letts LG, Mercer GJ, Saha JK, Schroeder JD, et al. (2000) Nitrosothiol esters of diclofenac synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J Med Chem 43:4005-4016.
22. Baylis C, Mitruka B, and Deng A (1992) Chronic blockade of NO synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Investig 90:278-281.
23. Beckman JS, Beckman TW, Chen J, Marshall PA, and Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from NO and superoxide. Proc Natl Acad Sci USA 87:1620-1624.
24. Beckman JS and Koppenol WH (1996) NO, superoxide, and peroxynitrite: the good, the bad and ugly. Am J Physiol 271:C1424-C1437.
25. Beiche F, Klein T, Nusing R, Neuhuber W, and Goppelt-Struebe M (1998) Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord. J Neuroimmunol 89:26-34.
26. Beiche F, Scheuerer S, Brune K, Geisslinger G, and Goppelt-Struebe M (1996) Up-regulation of COX-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390:165-169.
27. Beierwaltes WH (2002) COX-2 products compensate for inhibition of NO regulation of renal perfusion. Am J Physiol Renal Physiol 283:F68-F72.
28. Benjamin N, Dutton JAE, and Ritter JM (1991) Human vascular smooth muscle cells inhibit platelet aggregation when incubated with glyceryl trinitrate: evidence for generation of nitric oxide. Br J Pharmacol 102:847-850.
29. Benyo Z, Kiss G, Szabo C, Csaki C, and Kovach AG (1991) Importance of basal NO synthesis in regulation of myocardial blood flow. Cardiovasc Res 25:700-703.
30. Bieganski T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht CD, and Feussner KD (1983) Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. Biochim Biophys Acta 756:196-203.
31. Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, et al. (1999) 2,3-Diarylcyclopentenones as orally active, highly selective COX-2 inhibitors. J Med Chem 42:1274-1281.
32. Bley KR, Hunter JC, Eglen RM, and Smith JA (1998) The role of IP prostanoid receptors in inflammatory pain. Trends Pharmacol Sci 19:141-147.
33. Bogaty P, Hackett D, Davies G, and Maseri A (1994) Vasoreactivity of the culprit lesion in unstable angina. Circulation 90:5-11.
34. Bogle RG, Moncada S, Pearson JD, and Mann GE (1992) Identification of inhibitors of NO synthase that do not interact with the endothelial cell L-arginine transporter. Br J Pharmacol 105:768-770.
35. Boje KM and Arora PK (1992) Microglial-produced NO and reactive nitrogen oxides mediate neuronal cell death. Brain Res 587:250-256.
36. Bonaiuto C, McDonald PP, Rossi F, and Cassatella MA (1997) Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. J Neuroimmunol 77:51-56.
37. Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, and Moncada S (1993) NO synthase activity in ulcerative colitis and Crohn's disease. Lancet 342:338-340.
38. Brady AJ, Warren JB, Poole-Wilson PA, Williams TJ, and Harding SE (1993) NO attenuates cardiac myocyte contraction. Am J Physiol 265:H176-H182.
39. Breder CD, DeWitt D, and Kraig RP (1995) Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 355:296-315.
40. Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, and Snyder SH (1991) NO synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 7:615-624.
41. Bredt DS, Hwang PM, and Snyder SH (1990) Localization of NO synthase indicating a neural role for NO. Nature (Lond) 347:768-770.
42. Bryk R and Wolff DJ (1999) Pharmacological modulation of NO synthesis by mechanism-based inactivators and related inhibitors. Pharmacol Ther 84:157-178.
43. Butler AR and Williams DLH (1993) The physiological role of NO. Chem Soc Rev 1:233-241.
44. Calver A, Collier J, and Vallance P (1993) NO and cardiovascular control. Exp Physiol 78:303-326.
45. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Alvarez D, Al-Dalain S, Martinez G, Leon OS, and Springer JE (2003) Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 86:545-555.
46. Cao C, Matsumura K, Yamagata K, and Watanabe Y (1996) Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever. Brain Res 733:263-272.
47. Cena C, Lolli ML, Lazzarato L, Guaita E, Morini G, Coruzzi G, McElroy SP, Megson IL, Fruttero R, and Gasco A (2003) Antiinflammatory, gastrosparing and anti-platelet properties of new NO-donor esters of aspirin. J Med Chem 46:747-754.
48. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active COX-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560.
49. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, and Penneton M (1995) Pharmacology of a selective COX-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 274:1531-1537.
50. Chan CC and Rodger IW (1997) Selective COX-2 inhibitors as potential therapeutic agents for inflammatory diseases. Adv Exp Med Biol 407:157-161.
51. Chang YW, Jakobi R, McGinty A, Foschi M, Dunn MJ, and Sorokin A (2000) Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol 20:8571-8579.
52. Chao CC, Lokensgard JR, Sheng WS, Hu S, and Peterson PK (1997) IL-1-induced iNOS expression in human astrocytes via NF-kappa B. Neuroreport 8:3163-3166.
53. Chartrain NA, Geller DA, Koty PP, Sitrin NF, Nussler AK, Hoffman EP, Billiar TR, Hutchinson NI, and Mudgett JS (1994) Molecular cloning, structure and chromosomal localization of the human inducible NO synthase gene. J Biol Chem 269:6765-6772.
54. Chen C, Magee JC, and Bazan NG (2002) Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol 87: 2851-2857.
55. Chen LY and Mehta JL (1996) Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther 276:253-257.
56. Chen LY, Salafranca MN, and Mehta JL (1997) Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am J Physiol 273:H1854-H1859.
57. Cheng HF, Wang JL, Zhang MZ, McKanna JA, and Harris RC (2000) NO regulates renal cortical COX-2 expression. Am J Physiol Renal Physiol 279:F122-F129.
58. Chiou GC (2001) Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther 17:189-198.
59. Chong S and Fung HL (1991) Biochemical and pharmacological interactions between nitroglycerin and thiols. Effects of thiol structure on nitric oxide generation and tolerance reversal. Biochem J 42:1433-1439.
60. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, and Masini E (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121:1339-1347.
61. Clancy RM and Abramson SB (1995) NO: a novel mediator of inflammation. Proc Soc Exp Biol Med 210:93-101.
62. Colasanti M and Persichini T (2000) Nitric oxide: an inhibitor of NF-kappaB/Rel system in glial cells. Brain Res Bull 52:155-161.
63. Colasanti M and Suzuki H (2000) The dual personality of NO. Trends Pharmacol Sci 21:249-252.
64. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS, and Currie MG (1995) Suppression of adjuvant-induced arthritis by selective inhibition of inducible NO synthase. Eur J Pharmacol 273:15-24.
65. Corbett JA, Kwon G, Turk J, and McDaniel ML (1993) IL-1 beta induces the coexpression of both NO synthase and COX by islets of Langerhans: activation of COX by NO. Biochemistry 32:13767-13770.
66. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, and McDaniel ML (1992) Aminoguanidine, a novel inhibitor of NO formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556.
67. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Centorrino T, Lepore V, Terranova ML, Ciccolo A, Caputi AP, and Thiemermann C (2001) Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. Crit Care Med 29:102-111.
68. Cuzzocrea S, Misko TP, Costantino G, Mazzon E, Micali A, Caputi AP, Macarthur H, and Salvemini D (2000) Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion. FASEB J 14:1061-1072.
69. Cuzzocrea S, Zingarelli B, Hake P, Salzman AL, and Szabo C (1998) Antiinflammatory effects of mercaptoethylguanidine, a combined inhibitor of NO synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Radic Biol Med 24:450-459.
70. Davel L, D'Agostino A, Espanol A, Jasnis MA, Lauria de Cidre L, de Lustigc ES, and Sales ME (2002) NO synthase-COX interactions are involved in tumor cell angiogenesis and migration. J Biol Regul Homeostatic Agents 16:181-189.
71. Davidge ST, Baker PN, Laughlin MK, and Roberts JM (1995) Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. Circ Res 77:274-283.
72. Dawson VL (1995) NO: role in neurotoxicity. Clin Exp Pharmacol Physiol 22:305-308.
73. De Caterina R, Dorso CR, Tack-Goldman K, and Weksler BB (1985) Nitrates and endothelial prostacyclin production. Studies in vitro. Circulation 71:176-182.
74. De Caterina R, Giannessi D, Crea F, Chierchia S, Bernini W, Gazzetti P, and L'Abbate A (1984) Inhibition of platelet function by injectable isosorbide dinitrate. Am J Cardiol 53:1683-1687.
75. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, and Liao JK (1995) NO decreases cytokine-induced endothelial activation. NO selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Investig 96:60-68.
76. De Caterina R, Lombardi M, Bernini W, Giannessi D, Gazzetti P, and L'Abbate A (1990) Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. Am Heart J 119:855-862.
77. Deininger MH and Schluesener HJ (1999) Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma. J Neuroimmunol 95:202-208.
78. DelaTorre A, Schroeder RA, Bartlett ST, and Kuo PC (1998) Differential effects of nitric oxide-mediated S-nitrosylation on p50 and c-jun DNA binding. Surgery 124:137-141.
79. DelaTorre A, Schroeder RA, and Kuo PC (1997) Alteration of NF-kappa B p50 DNA binding kinetics by S-nitrosylation. Biochem Biophys Res Commun 238:703-706.
80. del Soldato P, Sorrentino R, and Pinto A (1999) NO-aspirins, a class of new anti-inflammatory and anti-thrombotic agents. Trends Pharmacol Sci 20:319-323.
81. DeWitt DL and Smith WL (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85:1412-1416.
82. Diaz-Cazorla M, Perez-Sala D, and Lamas S (1999) Dual effect of nitric oxide donors on cyclooxygenase-2 expression in human mesangial cells. J Am Soc Nephrol 10:943-952.
83. Dinerman JL, Dawson TM, Schell MJ, Snowman A, and Snyder SH (1994) Endothelial NO synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci USA 91:4214-4218.
84. Dinerman JL, Lowenstein CJ, and Snyder SH (1993) Molecular mechanisms of NO regulation. Potential relevance to cardiovascular disease. Circ Res 73:217-222.
85. Di Rosa M, Radomski M, Carnuccio R, and Moncada S (1990) Glucocorticoids inhibit the induction of NO synthase in macrophages. Biochem Biophys Res Commun 172:1246-1252.
86. Domoki F, Perciaccante JV, Puskar M, Bari F, and Busija DW (2001) Cyclooxygenase-2 inhibitor NS398 preserves neuronal function after hypoxia/ischemia in piglets. Neuroreport 12:4065-4068.
87. Doni MG, Whittle BJ, Palmer RM, and Moncada S (1988) Actions of nitric oxide on the release of prostacyclin from bovine endothelial cells in culture. Eur J Pharmacol 151:19-25.
88. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, and Lipsky PE (1998) COX in biology and disease. FASEB J 12:1063-1073.
89. Egan RW, Paxton J, and Kuehl FA Jr (1976) Mechanism for irreversible self-deactivation of PG synthetase. J Biol Chem 251:7329-7335.
90. Eliasson MJ, Blackshaw S, Schell MJ, and Snyder SH (1997) Neuronal NO synthase alternatively spliced forms: prominent functional localizations in the brain. Proc Natl Acad Sci USA 94:3396-3401.
91. Endoh M, Maiese K, Pulsinelli WA, and Wagner JA (1993) Reactive astrocytes express NADPH diaphorase in vivo after transient ischemia. Neurosci Lett 154: 125-128.
92. Esplugues JV (2002) NO as a signaling molecule in the nervous system. Br J Pharmacol 135:1079-1095.
93. Fantappiè O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A, and Mazzanti R (2002) The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 35:843-852.
94. Feelisch M (1991) The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol 17:S25-S33.
95. Feelisch M and Kelm M (1991) Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 180:286-293.
96. Feelisch M and Noack E (1987) Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 139:19-30.
97. Feldman PL, Griffith OW, Hong H, and Stuehr DJ (1993) Irreversible inactivation of macrophage and brain NO synthase by L-NG-methylarginine requires NADPH-dependent hydroxylation. J Med Chem 36:491-496.
98. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, and Michel T (1996) Endothelial NO synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271:22810-22814.
99. Flower RJ and Vane JR (1972) Inhibition of PG synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (Lond) 240:410-411.
100. Fredduzzi S, Mariucci G, Tantucci M, Del Soldato P, and Ambrosini MV (2001) Nitroaspirin (NCX 4016) reduces brain damage induced by focal cerebral ischemia in rat. Neurosci Lett 302:121-124.
101. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, and Vita JA (1998) Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98:1481-1486.
102. Fries JF (1998) Quality-of-life considerations with respect to arthritis and nonsteroidal anti-inflammatory drugs. Am J Med 104:14S-20S; discussion 21S-22S.
103. Fukuto JM, Stuehr DJ, Feldman PL, Bova MP, and Wong P (1993) Peracid oxidation of an N-hydroxyguanidine compound: a chemical model for the oxidation of N omega-hydroxyl-L-arginine by NO synthase. J Med Chem 36:2666-2670.
104. Fukuto JM, Wallace GC, Hszieh R, and Chaudhuri G (1992) Chemical oxidation of N-hydroxyguanidine compounds. Release of NO, nitroxyl and possible relationship to the mechanism of biological NO generation. Biochem Pharmacol 43:607-613.
105. Fulton D, Gratton JP, and Sessa WC (2001) Post-translational control of endothelial NO synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 299:818-824.
106. Furchgott RF and Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (Lond) 288:373-376.
107. Furfine ES, Harmon MF, Paith JE, Knowles RG, Salter M, Kiff RJ, Duffy C, Hazelwood R, Oplinger JA, and Garvey EP (1994) Potent and selective inhibition of human NO synthases. Selective inhibition of neuronal NO synthase by S-methyl-L- thiocitrulline and S-ethyl-L-thiocitrulline. J Biol Chem 269:26677-26683.
108. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, and Otomo S (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24:105-110.
109. Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, and Franchi A (2002) Correlation between NO and COX-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 299:517-524.
110. Gallo O, Fini-Storchi I, and Napolitano L (2000) Treatment of the contralateral negative neck in supraglottic cancer patients with unilateral node metastases (N1-3). Head Neck 22:386-392.
111. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, and Ziche M (1998) Role of NO in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587-596.
112. Gardiner SM, Compton AM, Bennett T, Palmer RM, and Moncada S (1990) Control of regional blood flow by endothelium-derived NO. Hypertension 15:486-492.
113. Garg UC and Hassid A (1989) NO-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Investig 83:1774-1777.
114. Garthwaite J (1991) Glutamate, NO and cell-cell signalling in the nervous system. Trends Neurosci 14:60-67.
115. Garthwaite J and Boulton CL (1995) NO signaling in the central nervous system. Annu Rev Physiol 57:683-706.
116. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ, and Knowles RG (1997) 1400W is a slow, tight binding and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 272:4959-4963.
117. Garvey EP, Oplinger JA, Tanoury GJ, Sherman PA, Fowler M, Marshall S, Harmon MF, Paith JE, and Furfine ES (1994) Potent and selective inhibition of human NO synthases. Inhibition by non-amino acid isothioureas. J Biol Chem 269:26669-26676.
118. Geis GS (1999) Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? J Rheumatol 26 (Suppl 56):31-36.
119. Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW, Resnick L, Mizrachi Y, Volsky DJ, et al. (1992) Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophageastroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 176:1703-1718.
120. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316.
121. Giardino I, Fard AK, Hatchell DL, and Brownlee M (1998) Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant-induced apoptosis. Diabetes 47:1114-1120.
122. Gibb W and Sun M (1996) Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 150:497-503.
123. Gilligan DM, Panza JA, Kilcoyne CM, Waclawiw MA, Casino PR, and Quyyumi AA (1994) Contribution of endothelium-derived NO to exercise-induced vasodilation. Circulation 90:2853-2858.
124. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, and Casamenti F (2002) Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38 MAPK pathway. Neurobiol Dis 11:257-274.
125. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, and Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614.
126. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, and Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241-246.
127. Gorlach C, Hortobagyi T, Hortobagyi S, and Benyo Z (2000) Neuronal NO synthase inhibitor has a neuroprotective effect in a rat model of brain injury. Restor Neurol Neurosci 17:71-76.
128. Govoni S, Masoero E, Favalli L, Rozza A, Scelsi R, Viappiani S, Buccellati C, Sala A, and Folco G (2001) The cyclooxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci Lett 303:91-94.
129. Green SJ, Nacy CA, Schreiber RD, Granger DL, Crawford RM, Meltzer MS, and Fortier AH (1993) Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun 61:689-698.
130. Griffiths MJ, Messent M, MacAllister RJ, and Evans TW (1993) Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 110:963-968.
131. Griscavage JM, Wilk S, and Ignarro LJ (1996) Inhibitors of the proteasome pathway interfere with induction of NO synthase in macrophages by blocking activation of transcription factor NF-kappa B. Proc Natl Acad Sci USA 93:3308-3312.
132. Grisham MB, Jourd'heuil D, and Wink DA (1999) NO. I. Physiological chemistry of NO and its metabolites: implications in inflammation. Am J Physiol 276:G315-G321.
133. Gryglewski RJ, Botting RM, and Vane JR (1988) Mediators produced by the endothelial cell. Hypertension 12:530-548.
134. Gryglewski RJ, Palmer RM, and Moncada S (1986) Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (Lond) 320:454-456.
135. Guastadisegni C, Minghetti L, Nicolini A, Polazzi E, Ade P, Balduzzi M, and Levi G (1997) Prostaglandin E2 synthesis is differentially affected by reactive nitrogen intermediates in cultured rat microglia and RAW 264.7 cells. FEBS Lett 413:314-318.
136. Guo Q, Wang LH, Ruan KH, and Kulmacz RJ (1996) Role of Val509 in timedependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J Biol Chem 271:19134-19139.
137. Gupta S, Srivastava M, Ahmad N, Bostwick DG, and Mukhtar H (2000) Over-expression of COX-2 in human prostate adenocarcinoma. Prostate 42:73-78.
138. Hajjar D, Lander H, Pearce F, Upmacis R, and Pomerantz K (1995) NO enhances prostaglandin-H synthase activity by a heme-independent mechanism: evidence implicating nitrosothiols. J Am Chem Soc 117:3340-3346.
139. Hallemeesch MM, Janssen BJ, De Jonge WJ, Soeters PB, Lamers WH, and Deutz NE (2003) NO production by cNOS and iNOS reflects blood pressure changes in LPS-challenged mice. Am J Physiol Endocrinol Metab 285:E871-E875.
140. Hardy P, Bhattacharya M, Abran D, Peri KG, Asselin P, Varma DR, and Chemtob S (1998) Increases in retinovascular prostaglandin receptor functions by cyclooxygenase-2 and -2 inhibition. Investig Ophthalmol Vis Sci 39:1888-1898.
141. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, and Breyer MD (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Investig 94:2504-2510.
142. Hartlage-Rubsamen M, Lemke R, and Schliebs R (1999) Interleukin-1beta, inducible nitric oxide synthase and nuclear factor-kappaB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/ interferon-gamma injection. J Neurosci Res 57:388-398.
143. Hawkey CJ (1996) Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol Suppl 220:124-127.
144. Hawkey CJ, Yeomans ND, and Gillon K (1998) Helicobacter pylori, NSAIDs and peptic ulcers. Lancet 351:61-62.
145. Hemler M and Lands WE (1976) Purification of the COX that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 251:5575-5579.
146. Henry D, Lim LL, Garcia Rodriguez LA, Perez GS, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312:1563-1566.
147. Herschman HR (1996) PG synthase 2. Biochim Biophys Acta 1299:125-140.
148. Hewett SJ (1999) Interferon-gamma reduces cyclooxygenase-2-mediated prostaglandin E2 production from primary mouse astrocytes independent of nitric oxide formation. J Neuroimmunol 94:134-143.
149. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, and Takahashi T (1998) Increased expression of COX 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761-3764.
150. Ho L and Pasinetti GM (2001) The potential of selective COX-2 inhibitors in inflammatory and other diseases. Drugs Today (Barc) 37:181-185.
151. Hobbs AJ, Fukuto JM, and Ignarro LJ (1994) Formation of free NO from L-arginine by NO synthase: direct enhancement of generation by superoxide dismutase. Proc Natl Acad Sci USA 91:10992-10996.
152. Hobbs AJ, Higgs A, and Moncada S (1999) Inhibition of NO synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 39:191-220.
153. Holscher C and Rose SP (1992) An inhibitor of NO synthesis prevents memory formation in the chick. Neurosci Lett 145:165-167.
154. Hood J and Granger HJ (1998) Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem 273:23504-23508.
155. Hoozemans JJ, Veerhuis R, Janssen I, Rozemuller AJ, and Eikelenboom P (2001) Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp Gerontol 36:559-570.
156. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, and Fishman MC (1995) Hypertension in mice lacking the gene for endothelial NO synthase. Nature (Lond) 377:239-242.
157. Hughes FJ, Buttery LD, Hukkanen MV, O'Donnell A, Maclouf J, and Polak JM (1999) Cytokine-induced prostaglandin E2 synthesis and COX-2 activity are regulated both by a NO-dependent and -independent mechanism in rat osteoblasts in vitro. J Biol Chem 274:1776-1782.
158. Hull M, Lieb K, and Fiebich BL (2002) Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr Med Chem 9:83-88.
159. Hurley SD, Olschowka JA, and O'Banion MK (2002) Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 19:1-15.
160. Iadecola C, Zhang F, Casey R, Nagayama M, and Ross ME (1997) Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible NO synthase gene. J Neurosci 17:9157-9164.
161. Iadecola C, Zhang F, and Xu X (1993) Role of NO synthase-containing vascular nerves in cerebrovasodilation elicited from cerebellum. Am J Physiol 264:R738-R746.
162. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, and del Soldato P (2001) Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 98:4202-4208.
163. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri G (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265-9269.
164. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, and Byrns RE (1993) Oxidation of NO in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed NO from L-arginine. Proc Natl Acad Sci USA 90:8103-8107.
165. Ignarro LJ, Napoli C, and Loscalzo J (2002) Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90:21-28.
166. Inoue T, Fukuo K, Morimoto S, Koh E, and Ogihara T (1993) NO mediates interleukin-1-induced prostaglandin E2 production by vascular smooth muscle cells. Biochem Biophys Res Commun 194:420-424.
167. Ischiropoulos H, Zhu L, and Beckman JS (1992) Peroxynitrite formation from macrophage-derived NO. Arch Biochem Biophys 298:446-451.
168. Janabi N, Chabrier S, and Tardieu M (1996) Endogenous nitric oxide activates prostaglandin F2 alpha production in human microglial cells but not in astrocytes: a study of interactions between eicosanoids, nitric oxide and superoxide anion (O2-) regulatory pathways. J Immunol 157:2129-2135.
169. Jaszewski R, Graham DY, and Stromatt SC (1992) Treatment of nonsteroidal anti-inflammatory drug-induced gastric ulcers with misoprostol. A double-blind multicenter study. Dig Dis Sci 37:1820-1824.
170. Jeremy JY, Yim AP, Wan S, and Angelini GD (2002) Oxidative stress, NO and vascular disease (Review). J Card Surg 17:324-327.
171. Jijon HB, Churchill T, Malfair D, Wessler A, Jewell LD, Parsons HG, and Madsen KL (2000) Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 279:G641-G651.
172. 2 in the perinatal brain: local synthesis and transfer across the blood brain barrier. J Lipid Mediators 6:487-492.
173. Jordan RA, Seth L, Henri DA, Wilen MM, and Franciosa JA (1985) Dose requirements and hemodynamic effects of transdermal nitroglycerin compared to placebo. Circulation 71:980-985.
174. Kadoyama K, Takahashi Y, Higashida H, Tanabe T, and Yoshimoto T (2001) Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 281:483-490.
175. Kambayashi T, Alexander HR, Fong M, and Strassmann G (1995) Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 154:3383-3390.
176. Kang RY, Freire-Moar J, Sigal E, and Chu CQ (1996) Expression of COX-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 35:711-718.
177. Kankuri E, Hamalainen M, Hukkanen M, Salmenpera P, Kivilaakso E, Vapaatalo H, and Moilanen E (2003) Suppression of pro-inflammatory cytokine release by selective inhibition of inducible NO synthase in mucosal explants from patients with ulcerative colitis. Scand J Gastroenterol 38:186-192.
178. Kankuri E, Vaali K, Knowles RG, Lahde M, Korpela R, Vapaatalo H, and Moilanen E (2001) Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3- (aminomethyl)benzyl] acetamidine. J Pharmacol Exp Ther 298:1128-1132.
179. Kaufmann WE, Worley PF, Pegg J, Bremer M, and Isakson P (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93:2317-2321.
180. Kawabe T, Harris PD, Zakaria EL, and Garrison RN (2003) Sepsis alters vessel contraction by adrenoceptor-induced NO and prostanoid. J Surg Res 110:352-359.
181. Kawamura T, Yamauchi T, Koyama M, Maruyama T, Akira T, and Nakamura N (1997) Expression of prostaglandin EP2 receptor mRNA in the rat spinal cord. Life Sci 61:2111-2116.
182. Kawasaki T, Oka N, Akiguchi I, Miyamoto K, Kaji R, and Shibasaki H (2001) Up-regulation of cyclooxygenase-2 in inflammatory demyelinating neuropathy. Acta Neuropathol (Berl) 101:154-158.
183. Kim EJ, Lee JE, Kwon KJ, Lee SH, Moon CH, and Baik EJ (2001) Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandin E(2) production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res 908: 1-9.
184. Kinoshita Y, Ueyama T, Senba E, Terada T, Nakai K, and Itakura T (2001) Expression of c-fos, heat shock protein 70, neurotrophins and cyclooxygenase-2 mRNA in response to focal cerebral ischemia/reperfusion in rats and their modification by magnesium sulfate. J Neurotrauma 18:435-445.
185. Klotz T, Bloch W, Volberg C, Engelmann U, and Addicks K (1998) Selective expression of inducible NO synthase in human prostate carcinoma. Cancer 82:1897-1903.
186. Knowles R, Dawson J, Waslidge N, Russell R, Angell A, Craig C, Schwartz S, Evans S, Whittle B, and Garvey E (2000) GW273629 is a highly selective, short-acting iNOS (NOS-2) inhibitor both in vitro and in vivo: beneficial effects in endotoxin shock, in Biology of Nitric Oxide, pp 48-55, vol 7, Portland Press, London.
187. Knowles RG and Moncada S (1994) NO synthases in mammals. Biochem J 298:249-258.
188. Kobayashi S, Katoh T, Iwamoto T, Bito H, and Sato S (2003) Effect of the neuronal NO synthase inhibitor 7-nitroindazole on the righting reflex ED50 and minimum alveolar concentration during sevoflurane anaesthesia in rats. Eur J Anaesthesiol 20:212-219.
189. Kobzik L, Bredt DS, Lowenstein CJ, Drazen J, Gaston B, Sugarbaker D, and Stamler JS (1993) Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 9:371-377.
190. Komori Y, Wallace GC, and Fukuto JM (1994) Inhibition of purified NO synthase from rat cerebellum and macrophage by L-arginine analogs. Arch Biochem Biophys 315:213-218.
191. Korbut R, Lidbury PS, and Vane JR (1990) Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet 335:669-671.
192. Kostic MM and Schrader J (1992) Role of NO in reactive hyperemia of the guinea pig heart. Circ Res 70:208-212.
193. Kovach AG, Szabo C, Benyo Z, Csaki C, Greenberg JH, and Reivich M (1992) Effects of NG-nitro-L-arginine and L-arginine on regional cerebral blood flow in the cat. J Physiol 449:183-196.
194. Kubes P, Suzuki M, and Granger DN (1991) NO: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651-4655.
195. Kunz T and Oliw EH (2001) The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur J Neurosci 13: 569-575.
196. Kurose I, Kubes P, Wolf R, Anderson DC, Paulson J, Miyasaka M, and Granger DN (1993) Inhibition of NO production. Mechanisms of vascular albumin leakage. Circ Res 73:164-171.
197. Kwon NS, Nathan CF, Gilker C, Griffith OW, Matthews DE, and Stuehr DJ (1990) L-Citrulline production from L-arginine by macrophage NO synthase. The ureido oxygen derives from dioxygen. J Biol Chem 265:13442-13445.
198. Laffi G, Foschi M, Masini E, Simoni A, Mugnai L, La Villa G, Barletta G, Mannaioni PF, and Gentilini P (1995) Increased production of NO by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 22:1666-1673.
199. Lancaster JR Jr and Hibbs JB Jr (1990) EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proc Natl Acad Sci USA 87:1223-1227.
200. Landino LM, Crews BC, Timmons MD, Morrow JD, and Marnett LJ (1996) Peroxynitrite, the coupling product of NO and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 93:15069-15074.
201. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, and Kluckman KD (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483-492.
202. Lapchak PA, Araujo DM, Song D, and Zivin JA (2001) Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. Stroke 32:1220-1225.
203. Laszlo F and Whittle BJ (1997) Actions of isoform-selective and non-selective NO synthase inhibitors on endotoxin-induced vascular leakage in rat colon. Eur J Pharmacol 334:99-102.
204. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, Masini E, Perfetto F, Tarquini R, Gentilini P, and Laffi G (2001) Hemodynamic, renal and endocrine effects of acute inhibition of NO synthase in compensated cirrhosis. Hepatology 34:19-27.
205. Lawson DL, Nichols WW, Metha P, and Metha JL (1991) Captopril-induced reversal of nitroglycerin tolerance: role of sulfhydryl group vs. ACE-inhibitory activity. J Cardiovasc Pharmacol 17:411-418.
206. Lechi C, Andrioli G, Gaino S, Tommasoli R, Zuliani V, Ortolani R, Degan M, Benoni G, Bellavite P, Lechi A, and Minuz P (1996a) The antiplatelet effects of a new nitroderivative of acetylsalicylic acid: an in vitro study of inhibition on early phase of platelet activation and on TXA2 production. Thromb Haemostasis 7:791-798.
207. Lechi C, Gaino S, Tommasoli R, Zuliani V, Bonapace S, Fontana L, Degan M, Lechi A, and Minuz P (1996b) In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. Blood Coagul Fibrinolysis 7:206-209.
208. Lee J, Ryu H, Ferrante RJ, Morris SM Jr, and Ratan RR (2003) Translational control of inducible NO synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci USA 100:4843-4848.
209. Lee PC, Salyapongse AN, Bragdon GA, Shears LL, Watkins SC, Edington HD, and Billiar TR (1999) Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 277:H1600-H1608.
210. Lee RK and Wurtman RJ (2000) Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. Ann NY Acad Sci 920:261-268.
211. Lepoivre M, Chenais B, Yapo A, Lemaire G, Thelander L, and Tenu JP (1990) Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. J Biol Chem 265:14143-14149.
212. Levine RE, Jaffe EA, Weksler BB, and Tack-Goldman K (1981) Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Investig 67:762-769.
213. 2 and PGF2 alpha receptors and receptor-coupled second messengers by cyclooxygenase inhibition in newborn pigs. J Pharmacol Exp Ther 272:15-19.
214. Lichtenthal PR, Rossi EC, Louis G, Rehnberg KA, Wade LD, Michaelis LL, Fung HL, and Patrignani P (1985) Dose-related prolongation of the bleeding time by intravenous nitroglycerin. Anesth Analg 64:30-33.
215. Lin AH, Bienkowski MJ, and Gorman RR (1989) Regulation of prostaglandin H synthase mRNA levels and PG biosynthesis by platelet-derived growth factor. J Biol Chem 264:17379-17383.
216. Loke KE, Curran CM, Messina EJ, Laycock SK, Shesely EG, Carretero OA, and Hintze TH (1999) Role of NO in the control of cardiac oxygen consumption in B(2)-kinin receptor knockout mice. Hypertension 34:563-567.
217. Loscalzo J (1981) N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Investig 67:762-769.
218. Luscher TF (1990) Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels. Lung 168 (Suppl):27-34.
219. Luscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, Yang ZH, Turina M, Gradel E, and Weber E (1988) Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 319:462-467.
220. Lynch SM, Morrow JD, Roberts LJ 2nd, and Frei B (1994) Formation of noncyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Investig 93:998-1004.
221. Maihofner C, Schlotzer-Schrehardt U, Guhring H, Zeilhofer HU, Naumann GO, Pahl A, Mardin C, Tamm ER, and Brune K (2001) Expression of COX-1 and -2 in normal and glaucomatous human eyes. Investig Ophthalmol Vis Sci 42:2616-2624.
222. Markey CM, Alward A, Weller PE, and Marnett LJ (1987) Quantitative studies of hydroperoxide reduction by prostaglandin H synthase. Reducing substrate specificity and the relationship of peroxidase to COX activities. J Biol Chem 262:6266-6279.
223. Martin-Sanz P, Hortelano S, Callejas NA, Goren N, Casado M, Zeini M, and Bosca L (2002) NO in liver inflammation and regeneration. Metab Brain Dis 17:325-334.
224. Massa PT and Wu C (1998) Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1. J Interferon Cytokine Res 18:499-507.
225. Matthews JR, Botting CH, Panico M, Morris HR, and Hay RT (1996) Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res 24:2236-2242.
226. McGeer PL and McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22:799-809.
227. McMillan K, Adler M, Auld DS, Baldwin JJ, Blasko E, Browne LJ, Chelsky D, Davey D, Dolle RE, Eagen KA, et al. (2000) Allosteric inhibitors of inducible NO synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci USA 97:1506-1511.
228. McMillan K and Masters BS (1995) Prokaryotic expression of the heme- and flavin-binding domains of rat neuronal NO synthase as distinct polypeptides: identification of the heme-binding proximal thiolate ligand as cysteine-415. Biochemistry 34:3686-3693.
229. Mebazaa A, De Keulenaer GW, Paqueron X, Andries LJ, Ratajczak P, Lanone S, Frelin C, Longrois D, Payen D, Brutsaert DL, and Sys SU (2001) Activation of cardiac endothelium as a compensatory component in endotoxin-induced cardiomyopathy: role of endothelin, PGs and NO. Circulation 104:3137-3144.
230. Mehta J, Chen LY, Kone BC, Mehta P, and Turner P (1995) Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 125:370-377.
231. Mehta J, Mehta P, and Ostrowski N (1993) Effects of nitroglycerin on human vascular prostacyclin and thromboxane A2 generation. J Lab Clin Med 102:116-125.
232. Mehta J, Mehta P, Roberts A, Faro R, Ostrowski N, and Brigmon L (1983) Comparative effects of nitroglycerin and nitroprusside on prostacyclin generation in adult human vessel wall. J Am Coll Cardiol 2:625-630.
233. Merlie JP, Fagan D, Mudd J, and Needleman P (1988) Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (COX). J Biol Chem 263:3550-3553.
234. Mete A and Connolly S (2003) Inhibitors of the NOS enzymes: a patent review. Drugs 6:57-65.
235. Minghetti L and Levi G (1998) Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 54:99-125.
236. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, and Levi G (1997a) Prostaglandin E2 downregulates inducible nitric oxide synthase expression in microglia by increasing cAMP levels. Adv Exp Med Biol 433:181-184.
237. Minghetti L, Polazzi E, Nicolini A, Creminon C, and Levi G (1996) Interferon-gamma and nitric oxide down-regulate lipopolysaccharide-induced prostanoid production in cultured rat microglial cells by inhibiting cyclooxygenase-2 expression. J Neurochem 66:1963-1970.
238. Minghetti L, Polazzi E, Nicolini A, Creminon C, and Levi G (1997b) Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur J Neurosci 9:934-940.
239. Minuz P, Lechi C, Tommasoli R, Gaino S, Degan M, Zuliani V, Bonapace S, Benoni G, Adami A, and Cuzzolin L (1995) Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Thromb Res 80:367-376.
240. Minuz P, Lechi C, and Zuliani V (1998) NO aspirins: antithrombotic activity of derivatives of acetylsalicylic acid releasing nitric oxide. Cardiovasc Drug Rev 16:31-47.
241. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, and Currie MG (1993) Selective inhibition of the inducible NO synthase by aminoguanidine. Eur J Pharmacol 233:119-125.
242. Misko TP, Trotter JL, and Cross AH (1995) Mediation of inflammation by encephalitogenic cells: interferon gamma induction of NO synthase and COX 2. J Neuroimmunol 61:195-204.
243. Mitchell JA, Belvisi MG, Akarasereenont P, Robbins RA, Kwon OJ, Croxtall J, Barnes PJ, and Vane JR (1994) Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 113:1008-1014.
244. Mitchell JA, Larkin S, and Williams TJ (1995) COX-2: regulation and relevance in inflammation. Biochem Pharmacol 50:1535-1542.
245. Mitchell JA and Warner TD (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128:1121-1132.
246. Mitchell MD, Lucas A, Etches PC, Brunt JD, and Turnbull AC (1978) Plasma prostaglandin levels during early neonatal life following term and pre-term delivery. Prostaglandins 16:319-326.
247. Miyamoto T, Ogino N, Yamamoto S, and Hayaishi O (1976) Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 251:2629-2636.
248. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, and Kasuga M (1997) Induction of COX 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-397.
249. 2 by human cultured astroglial cells. Br J Pharmacol 124:742-746.
250. Mollace V, Colasanti M, Persichini T, Bagetta G, Lauro GM, and Nistico G (1993) HIV gp120 glycoprotein stimulates the inducible isoform of NO synthase in human cultured astrocytoma cells. Biochem Biophys Res Commun 194:439-445.
251. Mollace V, Colasanti M, Rodino P, Lauro GM, and Nistico G (1994) HIV coating gp 120 glycoprotein-dependent prostaglandin E2 release by human cultured astrocytoma cells is regulated by nitric oxide formation. Biochem Biophys Res Commun 203:87-92.
252. Mollace V, Colasanti M, Rodino P, Lauro GM, Rotiroti D, and Nistico G (1995) NMDA-dependent prostaglandin E2 release by human cultured astroglial cells is driven by NO. Biochem Biophys Res Commun 215:793-799.
253. Mollace V, Muscoli C, Rotiroti D, and Nistico G (1997) Spontaneous induction of nitric oxide- and prostaglandin E2-release by hypoxic astroglial cells is modulated by interleukin 1 beta. Biochem Biophys Res Commun 238:916-919.
254. Mollace V, Salvemini D, and Vane JR (1991) Studies on the importance of the proposed L-arginine to nitric oxide pathway in platelets. Thromb Res 64:533-542.
255. Moncada S, Gryglewski R, Bunting S, and Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (Lond) 263:663-665.
256. Moncada S and Higgs EA (1995) Molecular mechanisms and therapeutic strategies related to NO. FASEB J 9:1319-1330.
257. Moncada S and Palmer RM (1991) Inhibition of the induction of NO synthase by glucocorticoids: yet another explanation for their anti-inflammatory effects? Trends Pharmacol Sci 12:130-131.
258. Moore KP, Darley-Usmar V, Morrow J, and Roberts LJ 2nd (1995) Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res 77:335-341.
259. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, and Currie MG (1994) L-N6-(1-Iminoethyl)lysine: a selective inhibitor of inducible NO synthase. J Med Chem 37:3886-3888.
260. Morais Cabral JH, Petosa C, Sutcliffe MJ, Raza S, Byron O, Poy F, Marfatia SM, Chishti AH, and Liddington RC (1996) Crystal structure of a PDZ domain. Nature (Lond) 382:649-652.
261. Morrison AR, Moritz H, and Needleman P (1978) Mechanism of enhanced renal PG biosynthesis in ureter obstruction. Role of de novo protein synthesis. J Biol Chem 253:8210-8212.
262. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, and Seidenberg B (1999) Analgesic efficacy of the COX-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 21:943-953.
263. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, and Sartor RB (2000) Impaired mucosal defense to acute colonic injury in mice lacking COX-1 or COX-2. J Clin Investig 105:469-478.
264. Moulian N, Truffault F, Gaudry-Talarmain YM, Serraf A, and Berrih-Aknin S (2001) In vivo and in vitro apoptosis of human thymocytes are associated with nitrotyrosine formation. Blood 97:3521-3530.
265. Mulsch A, Schray-Utz B, Mordvintcev PI, Hauschildt S, and Busse R (1993) Diethyldithiocarbamate inhibits induction of macrophage NO synthase. FEBS Lett 321:215-218.
266. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, and Hori M (1999) COX-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 94:451-455.
267. Muscoli C, Cuzzocrea S, Riley DP, Zweier JL, Thiemermann C, Wang ZQ, and Salvemini D (2003) On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol 140:445-460.
268. Nadaud S, Laumonnier Y, and Soubrier F (2000) Molecular aspects of the expression and regulation of endothelial NO synthase. J Soc Biol 194:131-135.
269. Nagayama M, Zhang F, and Iadecola C (1998) Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. J Cereb Blood Flow Metab 18:1107-1113.
270. Nakane M, Klinghofer V, Kuk JE, Donnelly JL, Budzik GP, Pollock JS, Basha F, and Carter GW (1995) Novel potent and selective inhibitors of inducible nitric oxide synthase. Mol Pharmacol 47:831-834.
271. Nakane M, Schmidt HH, Pollock JS, Forstermann U, and Murad F (1993) Cloned human brain NO synthase is highly expressed in skeletal muscle. FEBS Lett 316:175-180.
272. Nakatsugi S, Terada N, Yoshimura T, Horie Y, and Furukawa M (1996) Effects of nimesulide, a preferential COX-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats. Prostaglandins Leukotrienes Essent Fatty Acids 55:395-402.
273. Nantel F, Meadows E, Denis D, Connolly B, Metters KM, and Giaid A (1999) Immunolocalization of COX-2 in the macula densa of human elderly. FEBS Lett 457:475-477.
274. Naoki K, Kudo H, Suzuki K, Takeshita K, Miyao N, Ishii M, Sato N, Suzuki Y, Tsumura H, and Yamaguchi K (2002) NOS and COX isoforms and abnormal microvessel responses to CO2 and H+ in hyperoxia-injured lungs. Eur Respir J 20:43-51.
275. Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V, Condorelli M, Pinto A, and Ignarro LJ (2001) Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc Natl Acad Sci USA 98:2860-2864.
276. Nathan C (1992) NO as a secretory product of mammalian cells. FASEB J 6:3051-3064.
277. Nathan C and Xie QW (1994) NO synthases: roles, tolls and controls. Cell 78:915-918.
278. Needleman P and Johnson EM (1973) Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 184:709-715.
279. Needleman P and Manning PT (1999) Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis. Osteoarthritis Cartilage 7:367-370.
280. Needleman P, Turk J, Jakschik BA, Morrison AR, and Lefkowith JB (1986) Arachidonic acid metabolism. Annu Rev Biochem 55:69-102.
281. Newberry RD, Stenson WF, and Lorenz RG (1999) COX-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 5:900-906.
282. Nilsson BO, Kockum I, and Rosengren E (1996) Inhibition of diamine oxidase promotes uptake of putrescine from rat small intestine. Inflamm Res 45:513-518.
283. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, and Iadecola C (1998) Interaction between inducible NO synthase and COX- 2 after cerebral ischemia. Proc Natl Acad Sci USA 95:10966-10971.
284. Nogawa S, Zhang F, Ross ME, and Iadecola C (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17:2746-2755.
285. Notoya K, Jovanovic DV, Reboul P, Martel-Pelletier J, Mineau F, and Pelletier JP (2000) The induction of cell death in human osteoarthritis chondrocytes by NO is related to the production of prostaglandin E2 via the induction of COX-2. J Immunol 165:3402-3410.
286. Nussler AK and Billiar TR (1993) Inflammation, immunoregulation and inducible NO synthase. J Leukoc Biol 54:171-178.
287. O'Banion MK, Miller JC, Chang JW, Kaplan MD, and Coleman PD (1996) Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 66:2532-2540.
288. O'Banion MK, Sadowski HB, Winn V, and Young DA (1991) A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a COX-related protein. J Biol Chem 266:23261-23267.
289. Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A, and Narumiya S (1995) In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol 116:2828-2837.
290. Okumura K, Yasue H, Matsuyama K, Ogawa H, Morikami Y, Obata K, and Sakaino N (1992) Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol 19:753-758.
291. O'Neill MJ, Murray TK, McCarty DR, Hicks CA, Dell CP, Patrick KE, Ward MA, Osborne DJ, Wiernicki TR, Roman CR, et al. (2000) ARL 17477, a selective NO synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Brain Res 871:234-244.
292. Otto JC and Smith WL (1995) Prostaglandin endoperoxide synthases-1 and -2. J Lipid Mediat Cell Signal 12:139-156.
293. Ou P and Wolff SP (1993) Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 46:1139-1144.
294. Palmer RM, Ferrige AG, and Moncada S (1987) NO release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 327:524-526.
295. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, and Ziche M (1998) Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 273:4220-4226.
296. Parfenova H, Massie V, and Leffler CW (2000) Developmental changes in endothelium-derived vasorelaxant factors in cerebral circulation. Am J Physiol Heart Circ Physiol 278:H780-H788.
297. Parker JO (1987) Nitrate therapy in stable angina pectoris. N Engl J Med 316:1635-1642.
298. Parker JO, Farrell B, Lahey KA, and Rose BF (1987) Determinants of drug response in severe chronic heart failure. Activation of vasoconstrictor forced during vasodilator therapy. Circulation 76:572-576.
299. Parker JO and Fung HL (1984) Transdermal nitroglycerin in angina pectoris. Am J Cardiol 54:471-476.
300. Pasinetti GM (2001) Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. Arch Gerontol Geriatr 33:13-28.
301. Patel RP, McAndrew J, Sellak H, White CR, Jo H, Freeman BA, and Darley-Usmar VM (1999) Biological aspects of reactive nitrogen species. Biochim Biophys Acta 1411:385-400.
302. Peng HB, Libby P, and Liao JK (1995) Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 270:14214-14219.
303. Pereira CF, Boven LA, Middel J, Verhoef J, and Nottet HS (2000) Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions. J Leukoc Biol 68:423-428.
304. Peri KG, Hardy P, Li DY, Varma DR, and Chemtob S (1995) Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. J Biol Chem 270:24615-24620.
305. 2 biosynthesis in macrophages. J Leukoc Biol 65:792-799.
306. Pfeiffer S, Leopold E, Schmidt K, Brunner F, and Mayer B (1996) Inhibition of NO synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol 118:1433-1440.
307. Picot D, Loll PJ, and Garavito RM (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature (Lond) 367:243-249.
308. Pistelli A, Mollace V, Anggard E, Salvemini D, and Vane J (1994) Nitroblue tetrazolium inhibits the metabolism of glyceryl trinitrate to nitric oxide in bovine aortic smooth muscle cells. Biochem Pharmacol 47:1737-1742.
309. Pitcher GM and Henry JL (2002) Second phase of formalin-induced excitation of spinal dorsal horn neurons in spinalized rats is reversed by sciatic nerve block. Eur J Neurosci 15:1509-1515.
310. Pohl U, Holtz J, Busse R, and Bassenge E (1986) Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 8:37-44.
311. Poulos TL (1988) Cytochrome P450: molecular architecture, mechanism and prospects for rational inhibitor design (Review). Pharm Res (NY) 5:67-75.
312. Radi R, Beckman JS, Bush KM, and Freeman BA (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and NO. Arch Biochem Biophys 288:481-487.
313. Radomski MW, Palmer RM, and Moncada S (1987) The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and NO. Br J Pharmacol 92:639-646.
314. Rees DD, Palmer RM, Hodson HF, and Moncada S (1989a) A specific inhibitor of NO formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 96:418-424.
315. Rees DD, Palmer RM, and Moncada S (1989b) Role of endothelium-derived NO in the regulation of blood pressure. Proc Natl Acad Sci USA 86:3375-3378.
316. Rees DD, Palmer RM, Schulz R, Hodson HF, and Moncada S (1990) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101:746-752.
317. Ribeiro MO, Antunes E, De Nucci G, Lovisolo SM, and Zatz R (1992) Chronic inhibition of NO synthesis. A new model of arterial hypertension. Hypertension 20:298-303.
318. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, et al. (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121:105-117.
319. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, and Isola J (2002) Prognostic significance of elevated COX-2 expression in breast cancer. Cancer Res 62:632-635.
320. Rosen GD, Birkenmeier TM, Raz A, and Holtzman MJ (1989) Identification of a COX-related gene and its potential role in PG formation. Biochem Biophys Res Commun 164:1358-1365.
321. Roth GJ, Stanford N, and Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72:3073-3076.
322. Rowlands DK, Kao C, and Wise H (2001) Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro. Br J Pharmacol 133:13-22.
323. Rubanyi GM, Romero JC, and Vanhoutte PM (1986) Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 250:H1145-H1149.
324. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, and Mantyh PW (2003) Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 104:550-558.
325. Salvemini D, Currie MG, and Mollace V (1996) Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J Clin Investig 97:2562-2568.
326. Salvemini D, Korbut R, Anggard E, and Vane J (1990a) Immediate release of a NO-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 87:2593-2597.
327. Salvemini D, Korbut R, Anggard E, and Vane JR (1989) Lipopolysaccharide increases release of a NO-like factor from endothelial cells. Eur J Pharmacol 171:135-136.
328. Salvemini D, Manning PT, Zweifel B, Seibert K, Currie MG, Needleman P, and Masferrer JL (1995a) Dual inhibition of nitric oxide and prostaglandin contribute to the anti-inflammatory properties of nitric oxide synthase inhibitors. J Clin Investig 96:301-308.
329. Salvemini D and Masferrer JL (1996) Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo and in vivo studies. Methods Enzymol 269:12-25.
330. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, and Needleman P (1993a) Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90:7240-7244.
331. Salvemini D, Mollace V, Pistelli A, Angard E, and Vane J (1992a) Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by E. coli lipopolysaccharide. Proc Natl Acad Sci USA 89:982-986.
332. Salvemini D, Pistelli A, and Anggard E (1993b) Vascular anti-platelet action of 1,2-and 1,3-glyceryl dinitrate. Br J Pharmacol 110:937-942.
333. Salvemini D, Pistelli A, Mollace V, Angard E, and Vane J (1992b) The metabolism of glyceryl trinitrate to nitric oxide in the macrophage cell line J774 and its induction by E. coli lipopolysaccharide. Biochem Pharmacol 44:17-24.
334. Salvemini D, Pistelli A, and Vane J (1993c) Conversion of glyceryl trinitrate to nitric oxide in tolerant smooth muscle cells and endothelial cells. Br J Pharmacol 108:162-169.
335. Salvemini D, Radziszewski W, Korbut R, and Vane J (1990b) The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol 101:991-995.
336. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG, and Needleman P (1994) Endogenous nitric oxide markedly enhances prostaglandin production in a model of hydronephrosis. J Clin Investig 93:1940-1947.
337. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, and Needleman P (1995b) Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol 114:1171-1178.
338. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, and Woolf CJ (2001) Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature (Lond) 410:471-475.
339. Sanchez S, Martin MJ, Ortiz P, Motilva V, Herrerias JM, and Alarcon de la Lastra C (2002) Role of prostaglandins and nitric oxide in gastric damage induced by metamizol in rats. Inflamm Res 51:385-392.
340. Sanders DB, Larson DF, Jablonowski C, and Olsen L (1999) Differential expression of inducible NO synthase in septic shock. J Extra Corpor Technol 31:118-124.
341. Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, and Wilder RL (1992) In vivo COX expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Investig 89:97-108.
342. Sasaki T, Kitagawa K, Sugiura S, Omura-Matsuoka E, Tanaka S, Yagita Y, Okano H, Matsumoto M, and Hori M (2003) Implication of cyclooxygenase-2 on enhanced proliferation of neural progenitor cells in the adult mouse hippocampus after ischemia. J Neurosci Res 72:461-471.
343. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Nakama A, Takei Y, Nagano K, Matsui H, Kawano S, and Hori M (1997) Expression of the COX-2 gene in gastric epithelium. J Clin Gastroenterol 25 (Suppl 1):S105-S110.
344. Schafer AI, Alexander RW, and Handin RI (1980) Inhibition of platelet function by organic nitrate vasodilators. Blood 55:649-654.
345. Schmidt HH, Hofmann H, Schindler U, Shutenko ZS, Cunningham DD, and Feelisch M (1996) NO from NO synthase. Proc Natl Acad Sci USA 93:14492-14497.
346. Schroder H and Schror K (1992) Cytochrome P450 mediates bioactivation of glyceryl trinitrate in cultured cells, in Biology of Nitric Oxide, pp 65-73, vol 7, Portland Press, London.
347. 2 by organic nitrates and its significance for the antianginal effect. Scand J Lab Investig 44:33-38.
348. 2 after low dose nitroglycerin. Thromb Res 23:59-67.
349. Schwab JM, Brechtel K, Nguyen TD, and Schluesener HJ (2000a) Persistent accumulation of cyclooxygenase-1 (COX-1)-expressing microglia/macrophages and upregulation by endothelium following spinal cord injury. J Neuroimmunol 111:122-130.
350. Schwab JM, Nguyen TD, Postler E, Meyermann R, and Schluesener HJ (2000b) Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia. Acta Neuropathol 99: 609-614.
351. Seibert K, Masferrer JL, FU JY, Honda A, Raz A, and Needleman P (1991) The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity. Adv Prostaglandin Thromboxane Leukotriene Res 21A:45-51.
352. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, and Isakson P (1994) Pharmacological and biochemical demonstration of the role of COX 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017.
353. Servent D, Delaforge M, Ducrocq C, Mansuy D, and Lenfant M (1989) Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: involvement of cytochrome P450. Biochem Biophys Res Commun 163:1210-1216.
354. Sessa WC, Harrison JK, Barber CM, Zeng D, Durieux ME, D'Angelo DD, Lynch KR, and Peach MJ (1992) Molecular cloning and expression of a cDNA encoding endothelial cell NO synthase. J Biol Chem 267:15274-15276.
355. Shearer BG, Lee S, Oplinger JA, Frick LW, Garvey EP, and Furfine ES (1997) Substituted N-phenylisothioureas: potent inhibitors of human nitric oxide synthase with neuronal isoform selectivity. J Med Chem 40:1901-1905.
356. Shen W, Zhang X, Zhao G, Wolin MS, Sessa W, and Hintze TH (1995) Nitric oxide production and NO synthase gene expression contribute to vascular regulation during exercise. Med Sci Sports Exerc 27:1125-1134.
357. Sheng H, Shao J, Morrow JD, Beauchamp RD, and Dubois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362-366.
358. Sherman PA, Laubach VE, Reep BR, and Wood ER (1993) Purification and cDNA sequence of an inducible NO synthase from a human tumor cell line. Biochemistry 32:11600-11605.
359. Shibuki K and Okada D (1991) Endogenous NO release required for long-term synaptic depression in the cerebellum. Nature (Lond) 349:326-328.
360. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, and Bolli R (2002) Inducible NO synthase modulates COX-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90:602-608.
361. Silvagno F, Xia H, and Bredt DS (1996) Neuronal NO synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. J Biol Chem 19:11204-11208.
362. Simmons DL, Levy DB, Yannoni Y, and Erikson RL (1989) Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA 86:1178-1182.
363. Sirois J and Richards JS (1992) Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 267:6382-6388.
364. Slepko N and Levi G (1996) Progressive activation of adult microglial cells in vitro. Glia 16:241-246.
365. Slomiany BL and Slomiany A (2003) Platelet-activating factor modulates gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide. Biochem Biophys Res Commun 306:261-266.
366. Smalley WE and Dubois RN (1997) Colorectal cancer and nonsteroidal antiinflammatory drugs. Adv Pharmacol 39:1-20.
367. Smith WL and Lands WE (1972) Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland. Biochemistry 11:3276-3285.
368. Smith WL, Marnett LJ, and DeWitt DL (1991) Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49:153-179.
369. Smith WL, Meade EA, and Dewitt DL (1997) Interaction of PGH synthase isozymes-1 and -2 with nonsteroidal anti-inflammatory drugs. Adv Exp Med Biol 400A:189-196.
370. Sneddon JM and Vane JR (1988) Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci USA 85:2800-2804.
371. Snyder SH and Bredt DS (1992) Biological roles of NO. Sci Am 266:68-71.
372. Southan GJ, Szabo C, Connor MP, Salzman AL, and Thiemermann C (1995) Amidines are potent inhibitors of nitric oxide synthases: preferential inhibition of the inducible isoform. Eur J Pharmacol 291:311-318.
373. Spahr R, Knuttel A, Tholen A, and Feelisch M (1994) Biotransformation of organic nitrates to NO by cytosolic and microsomal glutathione-S-transferase, in Biology of Nitric Oxide, pp 15-24, Portland Press, London.
374. Spielman L, Winger D, Ho L, Aisen PS, Shohami E, and Pasinetti GM (2002) Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol (Berl) 103:157-162.
375. Stadler J, Harbrecht BG, Di Silvio M, Curran RD, Jordan ML, Simmons RL, and Billiar TR (1993) Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol 53:165-172.
376. Stadler P, Armstrong D, Margalith D, Saraga E, Stolte M, Lualdi P, Mautone G, and Blum AL (1991) Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. Dig Dis Sci 36:594-600.
377. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, and Loscalzo J (1992) NO circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 89:7674-7677.
378. Stamler JS and Loscalzo J (1991) The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. J Am Coll Cardiol 18:1529-1536.
379. Stamler JS and Meissner G (2001) Physiology of nitric oxide in skeletal muscle. Physiol Rev 81:209-237.
380. Stuehr DJ and Ikeda-Saito M (1992) Spectral characterization of brain and macrophage NO synthases. Cytochrome P-450-like hemeproteins that contain a flavin semiquinone radical. J Biol Chem 267:20547-20550.
381. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, and Vane JR (1995) Coinduction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 114:1335-1342.
382. Szabo C (1996) Physiological and pathophysiological roles of NO in the central nervous system. Brain Res Bull 41:131-141.
383. Szabo C (2003) Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 140-141:105-112.
384. Szabò C and Thiemermann C (1995) Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv Pharmacol 34:113-153.
385. Tagawa T, Imaizumi T, Harada S, Endo T, Shiramoto M, Hirooka Y, and Takeshita A (1994) NO influences neuronal activity in the nucleus tractus solitarius of rat brainstem slices. Circ Res 75:70-76.
386. Takadera T, Yumoto H, Tozuka Y, and Ohyashiki T (2002) Prostaglandin E(2) induces caspase-dependent apoptosis in rat cortical cells. Neurosci Lett 317:61-64.
387. Takeuchi K, Kagawa S, Mimaki H, Aoi M, and Kawauchi S (2002) COX and NOS isoforms involved in acid-induced duodenal bicarbonate secretion in rats. Dig Dis Sci 47:2116-2124.
388. Tayeh MA and Marletta MA (1989) Macrophage oxidation of L-arginine to NO, nitrite and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem 264:19654-19658.
389. Tegeder I, Niederberger E, Vetter G, Brautigam L, and Geisslinger G (2001) Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord. J Neurochem 79:777-786.
390. Tetsuka T, Daphna-Iken D, Miller BW, Guan Z, Baier LD, and Morrison AR (1996) NO amplifies interleukin 1-induced COX-2 expression in rat mesangial cells. J Clin Investig 97:2051-2056.
391. Thomas T, Nadackal TG, and Thomas K (2001) Aspirin and non-steroidal antiinflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 12:3263-3267.
392. Thomsen LL, Sargent JM, Williamson CJ, and Elgie AW (1998) NO synthase activity in fresh cells from ovarian tumour tissue: relationship of enzyme activity with clinical parameters of patients with ovarian cancer. Biochem Pharmacol 56:1365-1370.
393. Thomsen LL, Scott JM, Topley P, Knowles RG, Keerie AJ, and Frend AJ (1997) Selective inhibition of inducible NO synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res 57:3300-3304.
394. Thun MJ, Namboodiri MM, and Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596.
395. Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, Dawson TM, and Dawson VL (1997) Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci USA 94:2676-2680.
396. Tomimoto H, Shibata M, Ihara M, Akiguchi I, Ohtani R, and Budka H (2002) A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol (Berl) 104:601-607.
397. Trautman MS, Edwin SS, Collmer D, Dudley DJ, Simmons D, and Mitchell MD (1996) Prostaglandin H synthase-2 in human gestational tissues: regulation in amnion. Placenta 17:239-245.
398. Tsai AL, Wei C, and Kulmacz RJ (1994) Interaction between nitric oxide and prostaglandin H synthase. Arch Biochem Biophys 313:367-372.
399. Tsujii M and Dubois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501.
400. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, and Dubois RN (1998) COX regulates angiogenesis induced by colon cancer cells. Cell 93:705-716.
401. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, and Fahey TJ III (1999) COX-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59:987-990.
402. Upmacis RK, Deeb RS, and Hajjar DP (1999) Regulation of PGH2 synthase activity by nitrogen oxides. Biochemistry 38:12505-12513.
403. Vallance P, Collier J, and Moncada S (1989) NO synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res 23:1053-1057.
404. Vallance P, Leone A, Calver A, Collier J, and Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575.
405. Van der Ouderaa FJ, Buytenhek M, Nugteren DH, and Van Dorp DA (1977) Purification and characterisation of PG endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta 487:315-331.
406. Vane JR (1971) Inhibition of PG synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
407. Vane JR, Anggard EE, and Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27-36.
408. Vane JR and Botting RM (1996) Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 102:9-21.
409. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, and Willoughby DA (1994) Inducible isoforms of COX and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91:2046-2050.
410. Vanegas H and Schaible HG (2001) Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog Neurobiol 64:327-363.
411. Vartiainen N, Keksa-Goldsteine V, Goldsteins G, and Koistinaho J (2002) Aspirin provides cyclin-dependent kinase 5-dependent protection against subsequent hypoxia/reoxygenation damage in culture. J Neurochem 82:329-335.
412. Vayssettes-Courchay C, Bouysset F, and Verbeuren TJ (2002) Involvement of COX and NOS induction in the sympatho-activation during sepsis. Auton Neurosci 98:33-36.
413. 2 and altered fever response. Neuromolecular Med 3:15-28.
414. Volterra A, Trotti D, Cassutti P, Tromba C, Galimberti R, Lecchi P, and Racagni G (1992) A role for the arachidonic acid cascade in fast synaptic modulation: ion channels and transmitter uptake systems as target proteins. Adv Exp Med Biol 318:147-158.
415. Volterra A, Trotti D, and Racagni G (1994) Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms. Mol Pharmacol 46:986-992.
416. Von Knethen A and Brune B (1997) COX-2: an essential regulator of NO-mediated apoptosis. FASEB J 11:887-895.
417. Wagner DA, Young VR, and Tannenbaum SR (1983) Mammalian nitrate biosynthesis: incorporation of 15NH3 into nitrate is enhanced by endotoxin treatment. Proc Natl Acad Sci USA 80:4518-4521.
418. Wahl SM, McCartney-Francis N, Chan J, Dionne R, Ta L, and Orenstein JM (2003) Nitric oxide in experimental joint inflammation. Benefit or detriment? Cells Tissues Organs 174:26-33.
419. Walder CE, Thiemermann C, and Vane JR (1991) The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. Br J Pharmacol 102:967-973.
420. Walia M, Kwan CY, and Grover AK (2003) Effects of free radicals on coronary artery. Med Princ Pract 12:1-9.
421. Wallace JL (1999) Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol Sci 20:4-6.
422. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, and MacNaughton WK (1998) COX 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 115:101-109.
423. Wallace JL and Cirino G (1994) The development of gastrointestinal- sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 15:405-406.
424. Wallace JL and Del Soldato P (2003) The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 17:11-20.
425. Wallace JL, McKnight W, Wilson TL, Del Soldato P, and Cirino G (1997) Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. Am J Physiol 273:G1246-G1251.
426. Wallace JL, Muscara MN, McNight W, Dicay M, Del Soldato P, and Cirino G (1999) In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX 4016. Thromb Res 93:43-50.
427. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568.
428. Warner TD and Mitchell JA (2002) Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 99:13371-13373.
429. Watkins DN, Garlepp MJ, and Thompson PJ (1997) Regulation of the inducible cyclo-oxygenase pathway in human cultured airway epithelial (A549) cells by NO. Br J Pharmacol 121:1482-1488.
430. Webber RK, Metz S, Moore WM, Connor JR, Currie MG, Fok KF, Hagen TJ, Hansen DW Jr, Jerome GM, Manning PT, et al. Substituted 2-iminopiperidines as inhibitors of human nitric oxide synthase isoforms. J Med Chem 41:96-101.
431. Weinberg JB, Misukonis MA, Shami PJ, Mason SN, Sauls DL, Dittman WA, Wood ER, Smith GK, McDonald B, and Bachus KE (1995) Human mononuclear phagocyte inducible NO synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin and NO production by blood monocyte and peritoneal macrophages. Blood 86:1184-1195.
432. Whelton A (2001) Cyclooxygenase-2 inhibition and renal function. Ann Intern Med 134:1077-1078.
433. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, and Verburg KM (2001) COX-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8:85-95.
434. White KA and Marletta MA (1992) NO synthase is a cytochrome P-450 type hemoprotein. Biochemistry 31:6627-6631.
435. Whittle BJ, Lopez-Belmonte J, and Rees DD (1989) Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of NO formation. Br J Pharmacol 98:646-652.
436. Whittle BJ, Moncada S, and Vane JR (1978) Some actions of prostacyclin (PGI2) on the cardiovascular system and the gastric microcirculation. Acta Biol Med Ger 37:725-728.
437. Williams CS, Smalley W, and Dubois RN (1997) Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Investig 100:1325-1329.
438. Williams TJ and Peck MJ (1977) Role of PG-mediated vasodilatation in inflammation. Nature (Lond) 270:530-532.
439. Wink DA, Kasprzak KS, Maragos CM, Elespuru RK, Misra M, Dunams TM, Cebula TA, Koch WH, Andrews AW, and Allen JS (1991) DNA deaminating ability and genotoxicity of NO and its progenitors. Science (Wash DC) 254:1001-1003.
440. Wink DA and Mitchell JB (1998) Chemical biology of NO: insights into regulatory, cytotoxic and cytoprotective mechanisms of NO. Free Radic Biol Med 25:434-456.
441. Wolf G (1997) NO and NO synthase: biology, pathology, localization. Histol Histopathol 12:251-261.
442. Wolfe MM, Lichtenstein DR, and Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899.
443. Wolff DJ, Lubeskie A, and Umansky S (1994) The inhibition of the constitutive bovine endothelial nitric oxide synthase by imidazole and indazole agents. Arch Biochem Biophys 314:360-366.
444. Wu KK (1995) Inducible COX and NO synthase. Adv Pharmacol 33:179-207.
445. Xiang Z, Ho L, Yemul S, Zhao Z, Qing W, Pompl P, Kelley K, Dang A, Qing W, Teplow D, and Pasinetti GM (2002) Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr 10:271-278.
446. Xie W, Chipman JG, Robertson DL, Erikson RL, and Simmons DL (1991) Expression of a mitogen-responsive gene encoding PG synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692-2696.
447. Yagami T, Ueda K, Asakura K, Hayasaki-Kajiwara Y, Nakazato H, Sakaeda T, Hata S, Kuroda T, Takasu N, and Hori Y (2002) Group IB secretory phospholipase A2 induces neuronal cell death via apoptosis. J Neurochem 81:449-461.
448. Yagami T, Ueda K, Asakura K, Sakaeda T, Kuroda T, Hata S, Kambayashi Y, and Fujimoto M (2001) Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br J Pharmacol 134:673-681.
449. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, and Worley PF (1993) Expression of a mitogen-inducible COX in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11:371-386.
450. Yamamoto T and Nozaki-Taguchi N (1996) Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor and NS-398, a COX-2 selective inhibitor. Brain Res 739:104-110.
451. Yermakova A and O'Banion MK (2000) Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 6:1755-1776.
452. Yermakova AV and O'Banion MK (2001) Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging 22:823-836.
453. Yermakova AV, Rollins J, Callahan LM, Rogers J, and O'Banion MK (1999) Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 58:1135-1146.
454. Yildiz G, Demiryurek AT, Sahin-Erdemli I, and Kanzik I (1998) Comparison of antioxidant activities of aminoguanidine, methylguanidine and guanidine by luminol-enhanced chemiluminescence. Br J Pharmacol 124:905-910.
455. Yokoi I, Kabuto H, Habu H, and Mori A (1994) Alpha-guanidinoglutaric acid, an endogenous convulsant, as a novel nitric oxide synthase inhibitor. J Neurochem 63:1565-1567.
456. Yoshizumi M, Perrella MA, Burnett JC Jr, and Lee ME (1993) Tumor necrosis factor downregulates an endothelial NO synthase mRNA by shortening its half-life. Circ Res 73:205-209.
457. Young RJ, Beams RM, Carter K, Clark HA, Coe DM, Chambers CL, Davies PI, Dawson J, Drysdale MJ, Franzman KW, et al. (2000) Inhibition of inducible NO synthase by acetamidine derivatives of hetero-substituted lysine and homolysine. Bioorg Med Chem Lett 10:597-600.
458. Yu XJ, Li YJ, and Xiong Y (1994) Increase of an endogenous inhibitor of NO synthesis in serum of high cholesterol fed rabbits. Life Sci 54:753-758.
459. Zeiher AM, Fisslthaler B, Schray-Utz B, and Busse R (1995) NO modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 76:980-986.
460. Zhang B, Knight KR, Dowsing B, Guida E, Phan LH, Hickey MJ, Morrison WA, and Stewart AG (1997) Timing of administration of dexamethasone or the nitric oxide synthase inhibitor, nitro-L-arginine methyl ester, is critical for effective treatment of ischaemia-reperfusion injury to rat skeletal muscle. Clin Sci (Lond) 93:167-174.
461. Zhang J, Dawson VL, Dawson TM, and Snyder SH (1994) NO activation of poly(ADP-ribose) synthetase in neurotoxicity. Science (Wash DC) 263:687-689.
462. Zhang ZG, Reif D, Macdonald J, Tang WX, Kamp DK, Gentile RJ, Shakespeare WC, Murray RJ, and Chopp M (1996) ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 16:599-604.
463. Ziche M and Morbidelli L (2000) Nitric oxide and angiogenesis. J Neurooncol 50: 139-148.
464. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, and Schror K (1999) COX-2 expression in human esophageal carcinoma. Cancer Res 59:198-204.
465. Zingarelli B, Southan GJ, Gilad E, O'Connor M, Salzman AL, and Szabo C (1997) The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity. Br J Pharmacol 120:357-366.
466. Zou MH and Ullrich V (1996) Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett 382:101-104.